QCG
RAPP

Quadrant Capital Group’s Rapport Therapeutics RAPP Stock Holding History

Quadrant Capital Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.78K Hold
57
– – ﹤0.01% 2520
2025
Q4 		$1.73K Hold
57
– – ﹤0.01% 2540
2025
Q3 		$1.69K Buy
+57
New +$1.02K ﹤0.01% 2496

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Quadrant Capital Group's RAPP Position: Q1 2026 in Review

Quadrant Capital Group held its Rapport Therapeutics (RAPP) position steady in Q1 2026 at 57 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #2520.

Quadrant Capital Group first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Quadrant Capital Group held 57 shares of Rapport Therapeutics worth $1.78K as of Q1 2026.
  • Quadrant Capital Group left its Rapport Therapeutics share count unchanged in Q1 2026.
  • Rapport Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2520 holding.
  • Quadrant Capital Group first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.